



Prescriber Signature: _

Remicade (Infliximab) Patient Referral and Prescription Sheet

Remeaue (Immama), Latient Referral and Liesenphon Sheet										
Patient Information										
Patient Name:						Date:				
DOB:						Height:	Height:		l inches 🔲 cm	
Allergies:						Weight: ☐ Ibs ☐ kg				
Primary Diagnosis										
Diagnosis ICD-10 Diagnosis									ICD-10	
☐ Crohn's Disease of small intestine without complications K50.00					☐ Crohn's Disease of large intestine without complications				K50.10	
☐ Crohn's Disease, unspecified without complications K50.90					☐ Ulcerative Chronic pancolitis without complications K51.00					
☐ Plaque Psoriasis	☐ Psoriat	☐ Psoriatic Psoriasis L40.5								
☐ Rheumatoid arthritis, unspecified M00				Ankylo	☐ Ankylosing Spondylitis M4					
☐ Ulcerative Colitis, unspecified without complications K51.90					□ Other					
Medication Order										
☐ Remicade	☐ Renflexis	☐ Avsola	☐ Infliximab	☐ Inflec	ra	☐ Zymfentra	☐ Refills x one year			
Dosing: ☐ Initiation: Administer mg/kg IV over at least two hours at weeks 0, 2 and 6 per protocol ☐ Maintenance: Administer mg/kg IV over minutes every weeks ☐ Round to the nearest 100mg vial size OR exact dose of: mg ☐ 120mg SC every 2 weeks ☐ Refills										
□ Other										
						ent for ongoing nursin planted VAD when inf			ess and	
			Aı	cillary Orders						
Pre-medications: ☐ Diphenhydramine: 25mg PO 30 min pre-infusion ☐ Acetaminophen: 650mg PO 30 min pre-infusion ☐ Famotidine: 20 mg PO x1 dose ☐ Other pre-meds: ☐ Refill x one year					IV Flush Orders: □ Peripheral: NS 1-3 mL before/after use □ Implanted VAD: NS 5 to 10 mL before/after use and 10 mL postlab draw. Heparin (100 unit/mL) 3 to 5 mL final flush □ CVAD: NS 5 to 10 mL before/after use and 10 mL postlab draw Heparin (10 units/mL) 3 to 5 mL final flush □ Refill x one year					
Anaphylaxis Prot Administer epine	tocol: Epinephrine phrine IM in the ev		-	-		_				
Therapy Specific Documentation					Other Required Documentation					
Please include the following lab results CMP CBC LFTS CRP Infliximab Trough Levels Other				author H & P 0 Medica with da Hepati	 □ Patient Demographics – include insurance information. We will obtain authorization unless the insurance dictates otherwise. □ H & P OR progress note(s) □ Medication List- Please list past and present DMARDS/biologics below with dates of discontinue, if applicable □ Hepatitis B Surface Antigen □ Hepatitis B Core Antibody Total (not Core IgM) □ QuantiFERON-TB Gold 					
			Prov	ider Information						
Provider Name:					Provider Phone:					
Provider NPI:					Provider Fax:					
Provider Address:										
I authorize KabaFusion and										

CONFIDENTIALITY NOTICE: The following includes confidential, proprietary information that is the sole exclusive property of KabaFusion Holdings, LLC. No rights in, relating to, or derived from such information are assigned or otherwise transferred by this document, and the recipient of such information is subject to obligations of secrecy to and for the benefit of KabaFusion Holdings, LLC. Any unauthorized use or disclosure of such information is strictly prohibited. This message, together with any attachments, is intended only for the use of the individual or entity to which it is addressed and may contain information that is confidential and prohibited from disclosure. If you are not the intended recipient, you are hereby notified that any dissemination, or copying of this message, or any attachment, is strictly prohibited. If you have received this message in error, please notify the original sender immediately by telephone or by return fax and shred this document along with any other documents. Thank you.

Date: __